Riccabona Marcus, Koen Mark, Schindler Monica, Goedele Beckers, Pycha Armin, Lusuardi Lukas, Bauer Stuart B
Department of Paediatric Urology, Krankenhaus Barmherzige Schwestern, Linz, Austria.
J Urol. 2004 Feb;171(2 Pt 1):845-8; discussion 848. doi: 10.1097/01.ju.0000108892.35041.2d.
We prospectively evaluated the efficacy and durability of botulinum-A toxin in the treatment of detrusor hyperreflexia in children with myelomeningocele (MMC).
This study involved 15 patients with MMC (10 male and 5 female, mean age 5.8 years), all nonresponders to orally and intravesically administered anticholinergic medication and all on clean intermittent catheterization. Pretreatment assessment included a videourodynamic evaluation, an incontinence score and a mercaptoacetyltriglycine-3 renal scan. We injected 10 U/kg to a maximum of 360 U of botulinum-A toxin into the detrusor at 25 to 40 sites, sparing the trigone. Followup lasted between 12 and 30 months. All children underwent a urodynamic reevaluation, an assessment of the bladder capacity and an incontinence score at 3, 9 and 12 months after the first injection. A second intravesical injection was administered after 12 months and followup repeated as in the first year.
After the first injection treatment mean bladder reflex volume increased from 72.00 +/- 28.12 ml to 298 +/- 32.45 ml (mean +/- SD, p <0.001). Maximum detrusor pressure decreased from 78.76 +/- 23.14 cm H2O to 42.76 +/- 24.34 cm H2O (p <0.001). Maximum bladder capacity increased from 136.34 +/- 45.71 ml to 297.02 +/- 87.17 ml (p <0.001). Detrusor compliance increased from 18.29 +/- 27.19 ml/cm H2O to 51.17 +/- 38.17 ml/cm H2O (p <0.001). Of the 15 patients 13 became completely dry with CIC. The remaining 2 patients improved from score 3 to 1. Results after 9 months were similar to those obtained after 3 months. Mean durability of the effect of the drug was 10.5 months after the first as well as after the second intravesical injection.
Botulinum-A toxin is a safe alternative in the management of detrusor hyperreflexia in children with MMC. The preliminary results regarding urodynamic parameters and continence have been promising.
我们前瞻性评估了A型肉毒毒素治疗脊髓脊膜膨出(MMC)患儿逼尿肌反射亢进的疗效和持久性。
本研究纳入15例MMC患儿(男10例,女5例,平均年龄5.8岁),所有患儿对口服和膀胱内给予的抗胆碱能药物均无反应,均采用清洁间歇性导尿。治疗前评估包括视频尿动力学评估、尿失禁评分和巯基乙酰三甘氨酸-3肾扫描。我们在25至40个部位向逼尿肌注射10 U/kg的A型肉毒毒素,最大剂量为360 U,避开三角区。随访持续12至30个月。所有患儿在首次注射后3、9和12个月均接受尿动力学重新评估、膀胱容量评估和尿失禁评分。12个月后进行第二次膀胱内注射,并像第一年一样重复随访。
首次注射治疗后,平均膀胱反射容量从72.00±28.12 ml增加到298±32.45 ml(平均值±标准差,p<0.001)。最大逼尿肌压力从78.76±23.14 cm H2O降至42.76±24.34 cm H2O(p<0.001)。最大膀胱容量从136.34±45.71 ml增加到297.02±87.17 ml(p<0.001)。逼尿肌顺应性从18.29±27.19 ml/cm H2O增加到51.17±38.17 ml/cm H2O(p<0.001)。15例患儿中有13例通过清洁间歇性导尿完全干燥。其余2例患儿的评分从3分提高到1分。9个月后的结果与3个月后的结果相似。首次和第二次膀胱内注射后药物作用的平均持续时间均为10.5个月。
A型肉毒毒素是治疗MMC患儿逼尿肌反射亢进的一种安全替代方法。关于尿动力学参数和尿失禁的初步结果很有前景。